



MEDIA KIT

altasciences.com
media@altasciences.com

TABLE OF CONTENT

Who we are and what we offer _____	2
Mission and vision _____	3
The executive team _____	4
Company background _____	9
Industry recognition _____	11
Locations _____	12
Leaders in drug development _____	13
Featured coverage _____	14
Logos _____	15
Let's connect _____	15

WHO WE ARE

Altasciences is a mid-size **CRO** and **CDMO** dedicated to early-phase drug development.

For **over 30 years** we have been helping biotechnology and pharmaceutical companies bring life-changing therapeutics to patients faster with our novel and tailored approach.

[Visit our website](#)

WHAT WE OFFER

We simplify the sponsor's journey by streamlining and integrating all early-phase R&D services, from lead candidate selection to clinical proof of concept—and beyond.

[View our online brochure](#)





VISION

To be the one-stop solution for outsourced early-phase drug development, whether for one study, an entire program, or something in between.

OUR GOAL

Help sponsors get better drugs to the people who need them, faster.

MISSION

To offer clients a simple, comprehensive outsourcing solution that removes the need for numerous service providers during the early stages of drug development, helping them reach critical decision-making milestones sooner.

OUR MANTRA

Moving in unison to deliver big impact with a personal touch.

A VISION BECOMES REALITY

“

When I joined the team in 2010, my vision for Altasciences was to implement a new approach to early-phase drug development that would make outsourcing these critical phases easier. This was a vision to accelerate the journey by sponsors partnering with one CRO/CDMO and telling their story once—seamlessly and efficiently moving a drug from lead candidate selection to clinical proof of concept, and beyond.

By focusing on integration, communication, and quality science, we turned this vision into a reality.”

Chris Perkin
CEO



MEET OUR EXECUTIVE TEAM

Chris Perkin

Chief Executive Officer

Chris' career in the life sciences began in England in 1975 at Huntingdon Life Sciences as a toxicologist. During his 50-year career, he's served as Section Head for Preclinical Development at Beecham Pharmaceuticals, COO at CTBR Bio-Research, and SVP at Charles River Laboratories. In 2010, Chris joined Altasciences (formerly Algorithm Pharma) as CEO, assembling a team to reinvent the company into what we know today.

For his leadership at Altasciences, he was named one of the 100 Most Inspiring Leaders in the Life Science Industry by PharmaVoice for four consecutive years. In 2019, PharmaVoice named him a lifetime Red Jacket honoree.



[Connect on LinkedIn](#)

Get to know Chris:

- Listen to Chris discuss Altasciences' origins and the integration model at the heart of the company's DNA in [this podcast with The Canadian Business Quarterly](#).
- Read [Chris' interview with PharmaVoice](#) about transforming the industry with a people-focused approach.

Marie-Hélène Raigneau

President

Marie-Hélène has spent over 15 years in leadership roles within the drug development industry, at both preclinical and clinical research organizations. She began her career as Business Development Manager at Future Electronics and rose through the ranks at Charles River Laboratories to become Global Director of Marketing.

Marie-Hélène joined Altasciences in 2012, and has held a multitude of roles, helping to build, transform, and grow the business, including Executive Director of Business Development and Marketing (2012-2015), General Manager (2015-2018), Executive Vice President of Research Services (2018-2020), and Co-Chief Operating Officer (2020-2025). In 2025, Marie-Hélène was appointed President.



[Connect on LinkedIn](#)

Get to know Marie-Hélène:

- [Read this interview](#) with Insights Care Magazine about the most influential COOs in the healthcare industry.
- [Watch](#) as Marie-Hélène and other members of the executive team lead the conversation on change in a slow-to-change industry in a video for the 2024 Global Health Summit.



Steve Mason

Co-Chief Operating Officer

Steve has been in the drug development industry for 30 years. He began his career as a study director for Huntingdon Life Sciences in England in 1995, before transitioning in 2000 to CTBR Bio-Research (now Charles River Laboratories) in Canada, where he built the Safety Pharmacology Department. Then, Steve moved to China and established Charles River Laboratories' preclinical facility before becoming Vice President of Preclinical Services for WuXi App Tech in Suzhou (2011-2014).

Steve joined Altasciences in 2014 to build our preclinical business, and was promoted to Co-Chief Operating Officer in 2020.

[Connect on LinkedIn](#)

Get to know Steve:

- [Watch](#) as Steve and his colleagues discuss what it means to be an integrated CRO/CDMO.
- [Read this interview](#) with Insights Care about the most influential COOs in the healthcare industry.

Robert (Rob) Sabelli

Co-Chief Operating Officer

Rob began his career in 2007 as Senior Quality Assurance Inspector at Charles River Laboratories, overseeing the bioanalytical preclinical segment and managing government audits. Joining Altasciences in 2012 marked a transition into Business Development, where he helped grow the bioanalysis segment and oversaw key global accounts, rising through the ranks to become Chief Business Development Officer in 2021. In 2025, Rob was appointed Co-Chief Operating Officer.

[Connect on LinkedIn](#)

Get to know Rob:

- Watch as [Rob hosts a roundtable discussion](#) about seamless communication and collaboration in drug development.





Catherine (Cathy) Konidas

Chief Administrative Officer

Cathy began her career at CTBR Bio-Research (now Charles River Laboratories), becoming Senior Site Director of its Montréal facility. She joined Altasciences in 2010 as Vice President, Business Development, with the mandate of establishing solid front-end business offerings through the introduction of structured processes and metrics. She then transitioned to the role of Chief Commercial Officer, focused on expanding company offerings to align with commercial growth plans. As Chief Administrative Officer since 2021, Cathy oversees human resources and leads key initiatives that support organizational infrastructure and commercial strategy.

[Connect on LinkedIn](#)


Mariano Rodriguez, CPA CA, CPA USA

Chief Financial Officer

Mariano's career began at Ernst & Young in 1991 before joining Phoenix International as Global Director of Finance, where he completed eight acquisitions. He subsequently held several Chief Financial Officer positions with various companies, including Galileo Genomics, Neurochem, GFI Solutions, and Knox Technologies. Mariano joined Altasciences in 2018 as Chief Financial Officer.

[Connect on LinkedIn](#)





Dr. Gaetano Morelli, MD

Executive Vice President Medical Affairs, Chief Medical Officer

Dr. Morelli is a gastroenterologist with over 35 years of medical experience—25 of which have been spent in clinical research. He joined Altasciences in 2017 as a medical advisor and consultant for complex studies, and quickly moved into the role of Clinical Principal Investigator. He was appointed Chief Medical Officer in 2020 and Executive Vice President Medical Affairs in 2024.

In addition, Dr. Morelli is an associate professor of medicine at McGill University in Montréal, Québec, where he is involved in training medical students, residents, and specialty fellows.

[Connect on LinkedIn](#)

Get to know Dr. Morelli:

- **Watch** as Dr. Morelli reflects on his profoundly gratifying journey in medicine, clinical research, and academia in an episode of “Getting to the Heart of Science”.
- **Read** Dr. Morelli’s article for BioPharma Dive about the impact GLP-1 RAs will have on medicine and society.

Beatrice Setnik, PhD

Chief Scientific Officer

Beatrice joined Altasciences in 2019 as Chief Scientific Officer to provide consultation, scientific guidance, and strategic input on drug development programs. Beatrice is also an active member and participant in several associations and congresses, including the Cross Company Abuse Liability Council.

Beatrice is an adjunct professor at the University of Toronto’s Department of Pharmacology and Toxicology. She has published numerous research articles in internationally recognized peer-reviewed journals and has presented at over 200 scientific meetings and conferences.

In 2024, Beatrice was named a PharmaVoice 100 winner and one of the 30 Most Influential People in the Pharma Industry by The Medicine Maker. She was also shortlisted in the Industry Achiever category of the 2025 Citeline Awards.

[Connect on LinkedIn](#)



Get to know Beatrice:

- **Listen** as Beatrice moderates a discussion about drug addiction, in the first of a deeply moving three-part series of candid interviews with opioid and stimulant recreational drug users for the Altasciences podcast.
- Watch as Beatrice and her colleague **present a webinar** about pharmacodynamic measures to enhance the pharmacology, safety, and efficacy evaluation of CNS-active drugs in early clinical trials.



David Grégoire

Chief Quality and Compliance Officer

David's career began at CTBR Bio-Research (now Charles River Laboratories) in 2000 as a quality assurance inspector, before moving to Pharmascience where he developed and implemented a GxP quality system for bioanalytical and clinical operations. David joined Altasciences in 2012 as Director of Quality Assurance, and was appointed Chief Quality and Compliance Officer in 2021.

David is a member of the Canadian Chapter of the Society of Quality Assurance (CCSQA), for which he also served as Vice President (2013) and President (2014).

[Connect on LinkedIn](#)

Julie-Ann Cabana

Chief Marketing Officer

Julie-Ann's career in life sciences began in 2003 at CTBR Bio-Research (now Charles River Laboratories) in account management before becoming Head of Marketing for its Montréal facility. In 2008, she moved to China to help Charles River Laboratories establish its Shanghai location, serving as Director of Business Development and then Head of Global Marketing for its preclinical division. She then transitioned to WuXi AppTec in 2011 as Executive Director of Business Development. In 2014, Julie-Ann returned to North America to join Altasciences as Executive Director of Business Development. Julie-Ann was appointed Chief Marketing Officer in 2021.

[Connect on LinkedIn](#)



Get to know Julie-Ann:

- Read Julie-Ann's [interview with HealthCare+24](#).
- Listen as Julie-Ann [discusses rebranding on the Trailblazers Podcast](#).

30+ YEARS OF INNOVATION.

A LIMITLESS FUTURE AHEAD.

A Brief History of Altasciences

When Altasciences first became a CRO in 1995, the company went by a different name (Algorithme Pharma) and focused on generic drug testing and bioanalysis. Under Chris Perkin's leadership, the company launched its mission to **transform the drug development outsourcing paradigm**, embarking on a journey to **unify** and **streamline** early-phase drug development.

Thirty years later, Altasciences is now a world-leading mid-size CRO/CDMO with nine facilities and an office in the UK, providing sponsors with an **integrated, end-to-end solution** from lead candidate selection to clinical proof of concept—and beyond.

Watch as our CEO reflects on the moments that made us





Inaugurated as a CRO

Inaugurated new headquarters and a bioanalytical lab in Greater Montréal, QC

Chris Perkin joins the company as CEO

Expanded the clinical unit in Montréal, QC

Acquired a preclinical facility in Seattle, WA, and expanded the bioanalytical lab in Greater Montréal, QC

Acquired a clinical unit in Los Angeles, CA, and a preclinical facility in Scranton, PA

Expanded the bioanalytical lab in Columbia, MO

1995 > 1996 > 2001 > 2005 > 2010 > 2013 > 2014 > 2016 > 2018 > 2020 > 2021 > 2022 > 2023 > 2025

Built clinical unit and bioanalytical lab in Montréal, QC

Added another clinical unit in Montréal, QC


Created the Altasciences Group and acquired clinical pharmacology unit in Kansas, KS

Expanded the clinical unit Kansas City, KS

Acquired a CDMO facility in Philadelphia, PA

Acquired preclinical sites in Columbia, MO, and Sacramento, CA

Celebrated 30 years as a drug development solution company



RECOGNITION FOR ALTASCIENCES



Recognized in 2025.



Best Contract Research Organization (Full-Service Providers)
Finalist — 2023, 2022



Recognized in 2024, 2023, 2022, 2021, 2018, 2017, 2016, 2015, and 2014.



- **Beatrice Setnik**, Chief Scientific Officer — 2025
- **Chris Perkin**, CEO — 2019 (Lifetime Red Jacket Honoree), 2018, 2017, 2016, 2015



- **Industry Achiever** — Finalist — Beatrice Setnik, Chief Scientific Officer — 2025
- **Industry Achiever** — Finalist — Dr. David Nguyen, General Manager and Medical Director — 2025
- **Most Successful Early-Phase Research (Preclinical & Phase I)** — Finalist — 2025
- **Best Sponsor-Facing Technology Initiative** — Finalist — 2021

OUR OWNERS

novo holdings

In 2021, Altasciences was purchased by Novo Holdings, a world-leading life science investor part of the Novo Nordisk Foundation. Since 2014, the Foundation has donated more than \$3 billion in grants for scientific research, education and outreach, and humanitarian aid. Novo Holdings believes that scientific research enhances lives, boosts communities, and advances global health and wellbeing—and we couldn't agree more.



LOCATIONS

With nine R&D facilities strategically located across Canada and the United States, and an office in the UK, Altasciences provides clients with an integrated, comprehensive solution for all their early-phase drug development needs across multiple time zones.

PRECLINICAL RESEARCH FACILITIES

- Seattle, WA, U.S.A.
- Scranton, PA, U.S.A.
- Columbia, MO, U.S.A.
- Sacramento, CA, U.S.A.

CLINICAL RESEARCH FACILITIES

- Montréal, QC, Canada
- Kansas City, KS, U.S.A.
- Los Angeles, CA, U.S.A.

BIOANALYTICAL LABORATORIES

- Greater Montréal, QC, Canada
- Seattle, WA, U.S.A.
- Columbia, MO, U.S.A.

MANUFACTURING AND ANALYTICAL SERVICES FACILITY

- Philadelphia, PA, U.S.A.

[Learn more about our state-of-the-art facilities](#)

LEADERS IN DRUG DEVELOPMENT

We believe that sharing scientific knowledge is essential to advancing medicine and promoting global health and wellbeing. With over 30 years of industry experience, we've built a deep reservoir of expertise across all areas drug development—covering both generic and novel therapeutics. Our Altascientists (as we like to call them) are eager to share this knowledge in a variety of informative content.

THE ALTASCIENTIST

A scientific journal that delves into the processes, challenges, trends, and innovations in drug development. Available to read or listen to as an audiobook.

[Dive in](#)

WEBINARS

Experts from across Altasciences and key opinion leaders come together to deliver presentations on all aspects of drug development.

[Watch on-demand](#)

OFF-LABEL PODCAST

For the well-versed and the drug development curious, host Lisa Sanford and guests peel back the label on the drug development industry with candid conversations and an insider's perspective.

[Listen now](#)

THE BLOG


Monthly insights into the expansive field of life sciences, including case studies, scientific deep dives, and best practices and advice, along with valuable contributions from Altasciences' experts.

[Read on](#)

SCIENTIFIC PUBLICATIONS

From eBooks to scientific posters and case studies, these resources reveal detailed processes, techniques, and results from the R&D we've conducted over the years.

[Start browsing](#)



FEATURED COVERAGE

Whether it's sharing in our client's milestones or celebrating our own, the press plays a vital role in helping us circulate news about advancements within the drug development industry.

[View our full newsroom](#)

For press inquiries, please email media@altasciences.com.



SEPTEMBER 23, 2024

The Golden Era of GLP-1 Drugs: Where We Are and What Comes Next

[Read on](#)



JUNE 21, 2024

Pharma Tech Outlook's Top 20 CROs of 2024

[Read on](#)



FEBRUARY 26, 2024

Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic

[Read on](#)



APRIL 11, 2022

Alzamend Neuro Contracts With Altasciences and iResearch Atlanta to Manage and Conduct Its Phase IIA in Patients With Alzheimer's

[Read on](#)



NOVEMBER 12, 2024

Part One: Exploring Philadelphia's CDMOs

[Read on](#)



APRIL 5, 2024

Flipping the Drug Development Industry on Its Head

[Read on](#)



JUNE 1, 2023

Regulatory Affairs: Accelerating Drug Development Timelines

[Read on](#)



JULY 15, 2022

Canadian CRO Altasciences Kicks Off Client Manufacturing Expansion in Philadelphia

[Read on](#)

LOGOS

Download Instructions

1. Click on the download button below the image of the desired logo to open the image file in an Internet browser.
2. Right-click on the image in the browser and select “Save image as...”.

For other formats of our logo, please email media@altasciences.com.



Logo 1: Icon + Wordmark in Black

Style:

Gradient RGB

File Type:

.png (transparent background)

Download



Logo 2: Icon + Wordmark in White

Style:

Gradient RGB

File Type:

.png (transparent background)

Download



Logo 3: Icon Only

Style:

Gradient RGB

File Type:

.png (transparent background)

Download

LET'S CONNECT

Media Inquiries

media@altasciences.com

General Inquiries

contact@altasciences.com

Connect on LinkedIn

[@Altasciences](https://www.linkedin.com/company/altasciences)

Subscribe to our YouTube Channel

[@Altasciences](https://www.youtube.com/channel/UCAltasciences)

